UBS Group’s RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 RXIIW Stock Holding History

UBS Group’s Portfolio RXIIW Stock Details RXIIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,600	Closed	-$1K	–	8238
2016 Q4	$1K	Buy	+5,600	New	+$1.01K	﹤0.01%	7684

Other funds holding RXIIW

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

UBS Group's RXIIW Position: Q1 2017 in Review

UBS Group sold out of RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) in Q1 2017, closing a stake of 5,600 shares — an estimated $1K sold.

UBS Group first reported a position in RXIIW in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 4 funds tracked by Wall St. Rank hold RXIIW as of Q1 2017.

UBS Group reported no remaining RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 position as of Q1 2017 after selling out during the quarter.
UBS Group sold 5,600 RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 shares in Q1 2017, an estimated $1K.
UBS Group first reported a position in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 in Q4 2016 and held it in 1 quarter.
UBS Group's RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 position peaked at $1K in Q4 2016.
4 funds tracked by Wall St. Rank held RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 as of Q1 2017.

Based on UBS Group's 13F filing for Q1 2017, filed 12 May 2017.